NASDAQ:APGE Apogee Therapeutics Q1 2025 Earnings Report $81.16 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$81.12 -0.04 (-0.05%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Apogee Therapeutics EPS ResultsActual EPS-$0.95Consensus EPS -$1.19Beat/MissBeat by +$0.24One Year Ago EPSN/AApogee Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AApogee Therapeutics Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time6:00AM ETUpcoming EarningsApogee Therapeutics' Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Apogee Therapeutics Earnings HeadlinesApogee Therapeutics: Targeting Atopic DermatitisMay 21, 2026 | seekingalpha.comMichael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) StockMay 17, 2026 | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 25 at 1:00 AM | Weiss Ratings (Ad)Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial ResultsMay 11, 2026 | globenewswire.comRothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendationMay 2, 2026 | msn.comApogee Therapeutics Inc. (APGE): Primary Challenger to Established BlockbustersApril 27, 2026 | insidermonkey.comSee More Apogee Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Apogee Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apogee Therapeutics and other key companies, straight to your email. Email Address About Apogee TherapeuticsApogee Therapeutics (NASDAQ:APGE), Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders. The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis. Apogee is advancing a pipeline of additional RORγt-focused programs with potential applications across dermatology and immunology, including conditions such as alopecia areata and lichen planus. Preclinical studies have demonstrated target engagement and a favorable safety profile, supporting the company’s approach to address high-unmet needs in T cell-mediated disease. Headquartered in the United States, Apogee has established research and development operations to support medicinal chemistry, translational biology and clinical trial execution. The company collaborates with academic centers and contract research organizations to conduct multi-center studies in North America and Europe, generating data to inform regulatory strategy and future growth. Apogee’s management team brings together experienced leaders in immunology, drug discovery and clinical development. Drawing on a track record of advancing small molecule candidates through regulatory review, the leadership group is focused on driving its RORγt platform toward clinical proof-of-concept and preparing for potential partnerships or collaborations to expand the company’s reach in inflammatory and autoimmune therapeutics.View Apogee Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Earnings Beat Sends Stock To New HighsWas Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsApparel Earnings Winners and Losers: Ralph Lauren Takes OffWhy Walmart, Target and TJX Got Such Different Reactions After EarningsThe Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearOverextended, e.l.f. Beauty Is Primed to Rebound in Back Half Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
